[1] Y. Xu, M. Gong et al. Global trends and forecasts of breast cancer incidence and deaths. Sci. Data, 10, 334(2023).

[2] A. Roheel, A. Khan et al. Global epidemiology of breast cancer based on risk factors: A systematic review. Front. Oncol., 13, 1240098(2023).

[3] E. Rakha, S. Chan. Metastatic triple-negative breast cancer. Clin. Oncol., 23, 587-600(2011).

[4] A. Fancellu, N. Houssami et al. Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: Meta-analysis. Br. J. Surg., 108, 760-768(2021).

[5] C. H. Li, V. Karantza et al. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: A systematic literature review. Breast Cancer Res., 21, 1-14(2019).

[6] S. B. Evans, B. G. Haffty. Radiation therapy for triple-negative breast cancer. Triple-Negative Breast Cancer: A Clinician’s Guide, 71-82(2018).

[7] L. Li, F. Zhang et al. Immunotherapy for triple-negative breast cancer: Combination strategies to improve outcome. Cancers, 15, 321(2023).

[8] R. A. Leon-Ferre, M. P. Goetz. Advances in systemic therapies for triple negative breast cancer. BMJ, 381, e071674(2023).

[9] Y. Liu, Y. Hu et al. Advances in immunotherapy for triple-negative breast cancer. Mol. Cancer, 22, 145(2023).

[10] H.-Q. Tian, Y.-J. Wang et al. Effects of modified Ruji recipe in preventing relapse and metastasis of breast cancer patients with negative hormone receptor. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi Jiehe Zazhi (Chin. J. Integr. Traditional Western Med.), 37, 169-173(2017).

[11] J.-H. Lang, H.-Q. Tian et al. Therapeutic efficacy of Rujifang combined with chemotherapy for 41 patients with breast cancer. Pract. Clin. Med., 7, 40-43(2006).

[12] W. Jia, X. Lin et al. Rujifang inhibits triple-negative breast cancer growth via the PI3K/AKT pathway. J. Ethnopharmacol., 327, 118011(2024).

[13] F. Zhang, H. Li et al. In vivo flow cytometry reveals an anti-metastatic effect of Rujifang in triple-negative breast cancer. Cytometry Part A, 103, 723-731(2023).

[14] P. S. Steeg. Tumor metastasis: Mechanistic insights and clinical challenges. Nat. Med., 12, 895-904(2006).

[15] M. Cristofanilli, G. T. Budd et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England J. Med., 351, 781-791(2004).

[16] P. Salu, K. M. Reindl. Advancements in circulating tumor cell research: Bridging biology and clinical applications. Cancers, 16, 1213(2024).

[17] Q. Zhan, B. Liu et al. New insights into the correlations between circulating tumor cells and target organ metastasis. Signal Transduction Targeted Therapy, 8, 465(2023).

[18] L. A. García-Hernández, E. Martínez-Martínez et al. Optical detection of cancer cells using lab-on-a-chip. Biosensors, 13, 439(2023).

[19] M. Wu, B. Gao et al. Recent advances in Raman spectroscopy for skin diagnosis. J. Innovative Optical Health Sci., 16, 2330003(2023).

[20] L. Wang, X. Li et al. Automated retinal layer segmentation in optical coherence tomography images with intraretinal fluid. J. Innovative Optical Health Sci., 15, 2250019(2022).

[21] E. P. Darga, E. M. Dolce et al. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS One, 16, e0260124(2021).

[22] M. S. Loeian, S. M. Aghaei et al. Liquid biopsy using the nanotube-CTC-chip: Capture of invasive CTCs with high purity using preferential adherence in breast cancer patients. Lab on a Chip, 19, 1899-1915(2019).

[23] S.-K. Kraeft, A. Ladanyi et al. Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin. Cancer Res., 10, 3020-3028(2004).

[24] Z. Ao, X. Liu. Fiber-Optic Array Scanning Technology (FAST) for detection and molecular characterization of circulating tumor cells. Circulating Tumor Cells: Methods and Protocols, 235-246(2017).

[25] F. Ivich, I. Calderon et al. Ratiometric fluorescence sensing and quantification of circulating blood sodium sensors in mice in vivo. Biomed. Optics Express, 14, 5555-5568(2023).

[26] J. Pace, J. J. Lee et al. In vivo labeling and detection of circulating tumor cells in mice using OTL38. Mol. Imaging Biol., 26, 603-615(2024).

[27] D. Oza, F. Ivich et al. Lipid nanoparticle encapsulated large peritoneal macrophages migrate to the lungs via the systemic circulation in a model of clodronate-mediated lung-resident macrophage depletion. Theranostics, 14, 2526(2024).

[28] A. L. Williams, A. V. Scorzo et al. Two-color diffuse in vivo flow cytometer. J. Biomed. Optics, 29, 065003(2024).

[29] O. V. Grishin, N. A. Shushunova et al. Effect of pulsed laser parameters on photoacoustic flow cytometry efficiency in vitro and in vivo. Cytometry Part A, 103, 868-880(2023).

[30] C. Guan, B. He et al. Label-free in-vivo classification and tracking of red blood cells and platelets using Dynamic-YOLOv4 network. J. Innovative Optical Health Sci., 17, 2450009(2024).

[31] Y. Yu, Y. Zheng et al. Detection of cells by flow cytometry: Counting, imaging, and cell classification. J. Innovative Optical Health Sci., 16, 2330005(2023).

[32] J. Novak, I. Georgakoudi et al. In vivo flow cytometer for real-time detection and quantification of circulating cells. Optics Lett., 29, 77-79(2004).

[33] D. A. Sipkins, X. Wei et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature, 435, 969-973(2005).

[34] Z. Fan, J. A. Spencer et al. In vivo tracking of ‘color-coded’ effector, natural and induced regulatory T cells in the allograft response. Nat. Med., 16, 718-722(2010).

[35] Z.-C. Fan, J. Yan et al. Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model by in vivo flow cytometry assesses resection on metastasis. Cancer Res., 72, 2683-2691(2012).

[36] C. Xie, Z. Yang et al. Systemically infused mesenchymal stem cells show different homing profiles in healthy and tumor mouse models. Stem Cells Translational Med., 6, 1120(2017).

[37] D. Wei, K. Pang et al. Noninvasive monitoring of nanoparticle clearance and aggregation in blood circulation by in vivo flow cytometry. J. Controlled Release, 278, 66-73(2018).

[38] J. Zimmermann. Trash your agar plates! blood stream bacteria are now quantified by in vivo flow cytometry. Cytometry Part A, 97, 869-871(2020).

[39] S. Pulikkot, S. Paul et al. Monitoring circulating myeloid cells in peritonitis with an in vivo imaging flow cytometer. Biomolecules, 14, 886(2024).

[40] X. Zhu, Y. Suo et al. In vivo flow cytometry reveals a circadian rhythm of circulating tumor cells. Light: Sci. Appl., 10, 110(2021).

[41] J. Yan, Z. Fan et al. Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model. Cytometry Part A, 87, 1020-1028(2015).

[42] W. Jin, Y. Fu et al. In vivo fluorescence flow cytometry reveals that the nanoparticle tumor vaccine OVA@ HA-PEI effectively clears circulating tumor cells. Journal of Innovative Optical Health Sciences, 2450017(2024).

[43] X. Zhu, C. Wei et al. Monitoring radiofrequency therapy-induced tumor cell dissemination by in vivo flow cytometry. Cytometry Part A, 99, 593-600(2021).

[44] B. Zhuang, X. Zhu et al. Radiofrequency ablation induces tumor cell dissemination in a mouse model of hepatocellular carcinoma. Eur. Radiol. Exp., 7, 74(2023).

[45] X. Weng, D. Wei et al. Photodynamic therapy reduces metastasis of breast cancer by minimizing circulating tumor cells. Biomed. Optics Express, 12, 3878-3886(2021).

[46] S. Zaqout, L.-L. Becker et al. Immunofluorescence staining of paraffin sections step by step. Front. Neuroanatomy, 14, 582218(2020).

[47] S. Sin, F. Bonin et al. Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J. Natl. Cancer Inst., 103, 1323-1337(2011).

[48] M. J. Kwon. Matrix metalloproteinases as therapeutic targets in breast cancer. Front. Oncol., 12, 1108695(2023).

[49] F. Yang, X. Dong et al. Radix Bupleuri: A review of traditional uses, botany, phytochemistry, pharmacology, and toxicology. BioMed Res. Int., 2017, 7597596(2017).

[50] B. Wang, Y. Wang et al. Clinical study on RuJiFang to prevent postoperative recurrence and metastasis of breast cancer. West. J. Tradit. Chin. Med., 26, 101-104(2013).

[51] J. Dong, Y. Na et al. A review of the botany, ethnopharmacology, phytochemistry, analysis method and quality control, processing methods, pharmacological effects, pharmacokinetics and toxicity of codonopsis radix. Front. Pharmacol., 14, 1162036(2023).

[52] H. Li, A. Hung et al. Fritillariae thunbergii bulbus: Traditional uses, phytochemistry, pharmacodynamics, pharmacokinetics and toxicity. Int. J. Mol. Sci., 20, 1667(2019).

[53] H.-L. Li, H.-Q. Tian et al. Effect of Ruji recipe on proliferation of breast cancer cell line MDA-MB-231 and MCF-7 in vitro. J. Oncol. Chin. Med., 1, 10-44(2019).

[54] F. Bonin, A. Chiche et al. Kindlin-1 drives early steps of breast cancer metastasis. Cancer Commun., 42, 1036(2022).